Crossbow Therapeutics: Funding, Investors & Team (Oct 2026)
Crossbow Therapeutics develops immunotherapies that focus on engineering immune cells to target disease-specific antigens. The company builds platforms that combine antibody discovery with cell therapy approaches to direct immune responses toward cancer cells. Its work involves designing molecules that guide immune cells to recognize and eliminate targets with greater specificity. Crossbow Therapeutics conducts research and development activities that integrate protein engineering, immunology, and translational science. The company also advances preclinical programs to evaluate safety and effectiveness of its therapeutic candidates.
Crossbow Therapeutics has raised $77.0M across 1 funding round on record, the most recent a Series B of $77.0M announced in Mar 2026.
That round is above the $8.6M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Crossbow Therapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2026.
Crossbow Therapeutics Funding Rounds
Crossbow Therapeutics Founders and Leadership Team
Contact details for the Crossbow Therapeutics team: 1 of 1 has an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Crossbow Therapeutics Funding Compared to Other Biotechnology Startups
Crossbow Therapeutics' latest round of $77.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Biotechnology Startups Like Crossbow Therapeutics
Companies Similar to Crossbow Therapeutics
Arctic Therapeutics specializes in finding the genetic origins of common diseases and creating successful…
100XBIO is creating a cutting-edge platform for analyzing multiple T-cells automatically, aiming to…
Cellbox Solutions is a recently established technology firm that specializes in creative logistics solutions…
MEND is a company focused on life sciences, determined to assist individuals in achieving better health…
Nouscom is a company that develops an immunotherapy platform designed to produce modified viral vector…
Microbiotica develops treatments involving live bacteria found in the human microbiome, aiming to identify…
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop…
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
HydRegen, based in Oxford, UK, is a biotech firm that offers eco-friendly alternatives for the production of…
Desentum is a research-oriented biopharmaceutical company specialized in developing novel types of allergy…
Crossbow Therapeutics Funding FAQs
What does Crossbow Therapeutics do?
Crossbow Therapeutics develops immunotherapies that focus on engineering immune cells to target disease-specific antigens. The company builds platforms that combine antibody discovery with cell therapy approaches to direct immune responses toward cancer cells. Its work involves designing molecules that guide immune cells to recognize and eliminate targets with greater specificity. Crossbow Therapeutics conducts research and development activities that integrate protein engineering, immunology, and translational science. The company also advances preclinical programs to evaluate safety and effectiveness of its therapeutic candidates.
How much funding has Crossbow Therapeutics raised?
Crossbow Therapeutics has raised $77.0M across 1 round on record. The most recent is a Series B of $77.0M announced in Mar 2026.
When did Crossbow Therapeutics last raise funding?
Crossbow Therapeutics' most recent funding round on record is a Series B of $77.0M, announced in Mar 2026.
Who founded Crossbow Therapeutics?
FundedIQ lists Briggs Morrison (Founder) at Crossbow Therapeutics.
How many employees does Crossbow Therapeutics have?
Crossbow Therapeutics is in the 11-50 employee band.
How does Crossbow Therapeutics' funding compare to other Biotechnology startups?
Crossbow Therapeutics' latest round of $77.0M is above the $8.6M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Crossbow Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Crossbow Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.